How do you administer this medicine?
What is Caricin?
Caricin is used to treat bacterial infections in many different parts of the body. It is also used in combination with other medicines to treat duodenal ulcers caused by H. pylori. Caricin is also used to prevent and treat Mycobacterium avium complex (MAC) infection.
Caricin belongs to the class of medicines known as macrolide antibiotics. It works by killing bacteria or preventing their growth. However, Caricin will not work for colds, flu, or other virus infections.
Caricin is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Caricin is used in certain patients with the following medical condition:
- Legionnaires' disease.
Acute Bacterial Exacerbation of Chronic Bronchitis
Caricin (Filmtab, Granules) and Caricin XL Filmtab are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
Acute Maxillary Sinusitis
Caricin (Filmtab, Granules) and Caricin XL Filmtab (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
Caricin (Filmtab, Granules) and Caricin XL Filmtab are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to:
- Haemophilus influenzae (in adults)
- Haemophilus parainfluenzae (Caricin XL Filmtab in adults)
- Moraxella catarrhalis (Caricin XL Filmtab in adults)
- Mycoplasma pneumoniae, Streptococcus pneumoniae, Chlamydophila pneumoniae (Caricin XL Filmtab [in adults]; Caricin Filmtab and Caricin Granules [in adults and pediatric patients])
Caricin Filmtab and Caricin Granules are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy.
Uncomplicated Skin and Skin Structure Infections
Caricin Filmtab and Caricin Granules are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Staphylococcus aureus, or Streptococcus pyogenes.
Acute Otitis Media
Caricin Filmtab and Caricin Granules are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
Treatment and Prophylaxis of Disseminated Mycobacterial Infections
Caricin Filmtab and Caricin Granules are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Mycobacterium avium or Mycobacterium intracellulare in patients with advanced HIV infection.
Helicobacter pylori Infection and Duodenal Ulcer Disease
Caricin Filmtab is given in combination with other drugs in adults as described below to eradicate H. pylori. The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence.
- Caricin Filmtab in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori.
- Caricin Filmtab in combination with PRILOSEC (omeprazole) capsules are indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. Regimens which contain Caricin Filmtab as the single antibacterial agent are more likely to be associated with the development of Caricin resistance among patients who fail therapy. Caricin-containing regimens should not be used in patients with known or suspected Caricin resistant isolates because the efficacy of treatment is reduced in this setting.
Limitations of Use
Caricin XL Filmtab is indicated only for acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and community-acquired pneumonia in adults. The efficacy and safety of Caricin XL Filmtab in treating other infections for which Caricin Filmtab and Caricin Granules are approved have not been established.
There is resistance to macrolides in certain bacterial infections caused by Streptococcus pneumoniae and Staphylococcus aureus. Susceptibility testing should be performed when clinically indicated.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Caricin and other antibacterial drugs, Caricin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Caricin?
Use Caricin extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Caricin extended-release tablets by mouth with food.
- Swallow Caricin extended-release tablets whole. Do not break, crush, or chew before swallowing.
- If you are also taking zidovudine, do not take it within 2 hours before or after Caricin extended-release tablets.
- Caricin extended-release tablets works best if it is taken at the same time each day.
- To clear up your infection completely, take Caricin extended-release tablets for the full course of treatment. Keep taking it even if you feel better in a few days.
- Do not miss any doses. If you miss a dose of Caricin extended-release tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Caricin extended-release tablets.
Uses of Caricin in details
Caricin is used to treat bacterial infections of the skin, ears, sinuses and throat. It is also used in combination with other medicines to treat stomach ulcers caused by bacteria (Helicobacter pylori).
Caricin: Caricin 250 mg, Immediate-Release Tablet: One tablet contains 250mg Caricin. Tablet sodium content: 3.4 mg tablet.
Caricin Forte: Caricin 500 mg, Immediate-Release Tablet: One tablet contains 500mg Caricin. Tablet sodium content: 6.1 mg tablet.
Caricin MR: Caricin 500 mg, Modified-Release Tablet: One tablet contains 500 mg Caricin.
Caricin Paediatric Suspension 125 mg/5 mL: Caricin 125 mg/5 ml, Granules for
Oral Suspension (Pediatric Suspension): Each 5 ml of the granules for suspension contains 125 mg of Caricin.
Caricin Paediatric Suspension 250 mg/5 mL: Caricin 250 mg/5 ml, Granules for
Oral Suspension (Pediatric Suspension): Each 5 ml of the granules for suspension contains 250 mg of Caricin.
Caricin is a semisynthetic macrolide antibiotic obtained by substitution of a CH3O group for the hydroxyl (OH) group in position 6 of the erythromycin lactonic ring. Specifically, Caricin is 6-O-methyl erythromycin A. The white to off-white antibiotic powder is practically odorless, essentially insoluble in water and slightly soluble in ethanol, methanol and acetonitrile. Its molecular weight is 747.96.
Caricin Paediatric Suspension is an oral dosage form of Caricin for use primarily in children.
Excipients/Inactive Ingredients: Caricin: Tablet Core: Croscarmellose sodium, pregelatinized starch, microcrystalline cellulose, quinoline yellow (E104 aluminium lake), silicon dioxide, povidone, stearic acid, magnesium stearate, talc. Tablet Coating, Colour and Gloss Coating: Hypromellose, sorbitan monooleate, propylene glycol, titanium dioxide, vanillin, quinoline yellow (E104 aluminium lake), hydroxypropyl cellulose, sorbic acid.
Caricin Forte: Tablet Core: Croscarmellose sodium, microcrystalline cellulose, silicon dioxide, povidone, stearic acid, magnesium stearate, talc. Tablet Coating, Colour and Gloss Coating: Hypromellose, sorbitan monooleate, propylene glycol, titanium dioxide, vanillin, quinoline yellow (E104 aluminium lake), hydroxypropyl cellulose, sorbic acid.
Caricin MR: Tablet Core: Citric acid, sodium alginate, sodium calcium alginate, lactose, povidone, talc, stearic acid, magnesium stearate. Coating Solution: Hypromellose, polyethylene glycol, titanium dioxide, quinoline yellow (E104 aluminium lake), sorbic acid.
Caricin Paediatric Suspension: Granule Component and Coating: Carbopol carbomers, povidone, hypromellose phthalate, castor oil. Other Ingredients: Sucrose, xanthan gum, silicon dioxide, potassium sorbate, citric acid, maltodextrin, titanium dioxide, fruit punch flavor.
Caricin/Caricin Forte: Respiratory Tract/Skin and Soft Tissue Infections: Adults and Children ≥12 years: Usual Dose: 250 mg twice daily for 7 days, although this may be increased to 500 mg twice daily for up to 14 days in severe infections.
Children <12 years: Use Caricin Paediatric Suspension. The use of Caricin IR has not been studied in children <12 years.
Eradication of H. pylori: Adults and Elderly Triple Therapy Regimen: Caricin 500 mg twice daily in conjunction with amoxicillin 1000 mg twice daily and a proton-pump inhibitor in standard dose twice daily for 7 days.
Dual Therapy Regimen: Caricin 500 mg 3 times daily in conjunction with omeprazole 40 mg once daily for 14 days, followed by omeprazole 40 mg once daily for an additional 14 days. Supportive studies have been conducted with omeprazole 40 mg once daily for 14 days.
Renal Impairment: Dosage adjustments are not usually required except in patients with severe renal impairment (creatinine clearance <30 mL/min). If adjustment is necessary, the total daily dosage should be reduced by ½ eg, 250 mg once daily or 250 mg twice daily in more severe infections.
Caricin may be given without regard to meals as food does not affect the extent of bioavailability.
Caricin MR: Adults and Children >12 years: Usual Recommended
Dosage: 1 modified-release tab daily to be taken with food. In more severe infections, the dosage can be increased to 2 tabs daily. The usual duration of treatment is 7-14 days.
Children <12 years: Use Caricin Paediatric Suspension. The use of Caricin MR has not been studied in children <12 years.
Renal Impairment: Caricin MR should not be used in patients with renal impairment (creatinine clearance <30 mL/min). Caricin immediate-release tablets may be used in this patient population.
Do not crush or chew Caricin MR tablets.
Caricin Paediatric Suspension: Children 6 months to 12 years: Clinical trials have been conducted using Caricin Pediatric Suspension in children 6 months-12 years. Therefore, children 6 months-12 years of age should use Caricin Pediatric Suspension (granules for oral suspension).
Dosage: 7.5 mg/kg twice daily up to a maximum dose of 500 mg twice daily for nonmycobacterial infections. The usual duration of treatment is for 5-10 days depending on the pathogen involved and the severity of the condition. The prepared suspension can be taken with or without meals, and can be taken with milk.
Table 3 is a suggested guide for determining
Dosage: See Table 3.
Patients with Renal Impairment: In children with creatinine clearance <30 mL/min, the dosage of Caricin should be reduced by ½ ie, up to 250 mg once daily or 250 mg twice daily in more severe infections. Dosage should not be continued >14 days in these patients.
Patients with Mycobacterial Infections: In children with disseminated or localized mycobacterial infections (M. avium, M. intracellulare, M. chelonae, M. fortuitum, M. kansasii), the recommended dose is 15-30 mg/kg/day in 2 divided doses.
Treatment with Caricin should continue as long as clinical benefit is demonstrated. The addition of other antimycobacterial agents may be of benefit.
Caricin: Data available to date indicate that Caricin is metabolized primarily by the hepatic cytochrome P-450 3A (CYP3A) isozyme. This is an important mechanism determining many drug interactions.
The metabolism of other drugs by this system may be inhibited by concomitant administration with Caricin and may be associated with elevations in serum levels of drug classes known or suspected to be metabolized by the same CYP450 and CYP3A isozyme.
Other Drug Interactions: Elevated digoxin serum concentrations have been reported in patients receiving Caricin tablets and digoxin concomitantly. Monitoring of serum digoxin levels should be considered.
There have been post-marketing reports of Torsades de pointes occurring with concurrent use of Caricin and quinidine or disopyramide. Serum levels of these medications should be monitored during Caricin therapy.
Rhabdomyolysis coincident with the co-administration of Caricin and the HMG-CoA reductase inhibitors eg, lovastatin and simvastatin has rarely been reported.
Antiretroviral Drug Interactions: Simultaneous oral administration of Caricin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because Caricin appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of Caricin and zidovudine. This interaction does not appear to occur in pediatric HIV-infected patients taking Caricin suspension with zidovudine or dideoxyinosine.
A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every 8 hrs and Caricin 500 mg every 12 hrs resulted in a marked inhibition of the metabolism of Caricin.
For patients with renal impairment, the following dosage adjustments should be considered: For patients with CrCl 30-60 mL/min, the dose of Caricin should be reduced by 50%. For patients with CrCl <30 mL, the dose of Caricin should be decreased by 75%. Doses of Caricin >1 g/day should not be co-administered with ritonavir.
Caricin OD: As with other macrolide antibiotics, the use of Caricin in patients concurrently taking drugs metabolized by the cytochrome P-450 system (eg, cilostazol, methylprednisolone, anticoagulants eg, warfarin, quinidine, sildenafil, ergot alkaloids, alprazolam, triazolam, midazolam, disopyramide, lovastatin, rifabutin, phenytoin, cyclosporin, vinblastine, valproate and tacrolimus) may be associated with elevations in serum levels of these other drugs.
Digoxin: Elevated digoxin serum concentrations have been reported in patients receiving Caricin tablets and digoxin concomitantly. Monitoring of serum digoxin levels should be considered.
Quinidine/Disopyramide: There have been post-marketed reports of Torsades de pointes occurring with concurrent use of Caricin and quinidine or disopyramide. Electrocardiogram and serum levels of these medications should be monitored during Caricin therapy.
HMG-CoA Reductase Inhibitors: As with other macrolides, Caricin has been reported to increase concentrations of HMG-CoA reductase inhibitors (eg, statins). Rhabdomyolysis has also been reported in patients taking these drugs concomitantly.
Theophylline, Carbamazepine: The administration of Caricin to patients receiving theophylline or carbamazepine has been associated with an increase in serum theophylline or carbamazepine levels.
Oral Anticoagulants:Concomitant administration of Caricin and oral anticoagulants may potentiate the effects of oral anticoagulants. Prothrombin time should be carefully monitored while patients are receiving Caricin and oral anticoagulants simultaneously.
Ritonavir: Ritonavir increases AUC, Cmax and Cmin of Caricin when administered concurrently. Because of the large therapeutic window for Caricin, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with CrCl 30-60 mL/min, the dose of Caricin should be reduced by 50%. For patients with CrCl <30 mL/min, the dose of Caricin should be decreased by 75%. Doses of Caricin >1 g/day should not be co-administered with ritonavir.
Efavirenz, Nevirapine, Rifampicin and Rifabutin: Strong inducers of the cytochrome P-450 metabolism system eg, efavirenz, nevirapine, rifampicin and rifabutin may accelerate the metabolism of Caricin and thus, lower the plasma levels of Caricin. Since the microbiological activities of Caricin and 14-OH-Caricin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of Caricin and enzyme inducers.
Sildenafil, Tadalafil and Vardenafil: Each of these phosphodiesterase inhibitors is metabolized, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered Caricin. Reduction in sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with Caricin.
Triazolam: Drug interactions and CNS effects (eg, somnolence and confusion) with the concomitant use of Caricin and triazolam have been reported. Monitoring the patient for increased CNS pharmacological effects is suggested.
Colchicine: When Caricin and colchicine are administered together, inhibition of Pgp and/or CYP3A by Caricin may lead to increased exposure to colchicine. Patients should be monitored for clinical symptoms of colchicine toxicity.
Itraconazole: Both Caricin and itraconazole are substrates and inhibitors of CYP3A. Caricin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of Caricin. Patients taking itraconazole and Caricin concomitantly should be monitored closely for signs and symptoms of increased or prolonged pharmacological effect.
Zidovudine: Simultaneous oral administration of Caricin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. This interaction does not appear to occur in pediatric HIV-infected patients taking Caricin suspension with zidovudine or dideoxyinosine.
Caricin side effects
the most frequently reported events in adults taking Caricin tablets (Caricin tablets, USP) were diarrhea (3%), nausea (3%), abnormal taste (3%), dyspepsia (2%), abdominal pain/discomfort (2%), and headache (2%). In pediatric patients, the most frequently reported events were diarrhea (6%), vomiting (6%), abdominal pain (3%), rash (3%), and headache (2%). Most of these events were described as mild or moderate in severity. Of the reported adverse events, only 1% was described as severe.
The most frequently reported events in adults taking Caricin XL (Caricin extended-release tablets) were diarrhea (6%), abnormal taste (7%), and nausea (3%). Most of these events were described as mild or moderate in severity. Of the reported adverse events, less than 1% were described as severe.
In the acute exacerbation of chronic bronchitis and acute maxillary sinusitis studies overall gastrointestinal adverse events were reported by a similar proportion of patients taking either Caricin tablets or Caricin XL tablets; however, patients taking Caricin XL tablets reported significantly less severe gastrointestinal symptoms compared to patients taking Caricin tablets. In addition, patients taking Caricin XL tablets had significantly fewer premature discontinuations for drug-related gastrointestinal or abnormal taste adverse events compared to Caricin tablets.
In community-acquired pneumonia studies conducted in adults comparing Caricin to erythromycin base or erythromycin stearate, there were fewer adverse events involving the digestive system in Caricin-treated patients compared to erythromycin-treated patients (13% vs 32%; p < 0.01). Twenty percent of erythromycin-treated patients discontinued therapy due to adverse events compared to 4% of Caricin-treated patients.
In two U.S. studies of acute otitis media comparing Caricin to amoxicillin/potassium clavulanate in pediatric patients, there were fewer adverse events involving the digestive system in Caricin-treated patients compared to amoxicillin/potassium clavulanate-treated patients (21% vs. 40%, p < 0.001). One-third as many Caricin-treated patients reported diarrhea as did amoxicillin/potassium clavulanate-treated patients.
Allergic reactions ranging from urticaria and mild skin eruptions to rare cases of anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred. Other spontaneously reported adverse events include glossitis, stomatitis, oral moniliasis, anorexia, vomiting, pancreatitis, tongue discoloration, thrombocytopenia, leukopenia, neutropenia, and dizziness. There have been reports of tooth discoloration in patients treated with Caricin. Tooth discoloration is usually reversible with professional dental cleaning. There have been isolated reports of hearing loss, which is usually reversible, occurring chiefly in elderly women. Reports of alterations of the sense of smell including smell loss, usually in conjunction with taste perversion or taste loss, have also been reported.
Transient CNS events including anxiety, behavioral changes, confusional states, convulsions, depersonalization, disorientation, hallucinations, insomnia, depression, manic behavior, nightmares, psychosis, tinnitus, tremor, and vertigo have been reported during post-marketing surveillance. Events usually resolve with discontinuation of the drug.
Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been infrequently reported with Caricin. This hepatic dysfunction may be severe and is usually reversible. In very rare instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications.
There have been rare reports of hypoglycemia, some of which have occurred in patients taking oral hypoglycemic agents or insulin.
There have been post-marketing reports of tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times.
As with other macrolides, Caricin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes.
There have been reports of interstitial nephritis coincident with Caricin use.
There have been post-marketing reports of colchicine toxicity with concomitant use of Caricin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency.
Deaths have been reported in some such patients.
Changes in Laboratory Values
Changes in laboratory values with possible clinical significance were as follows:
Elevated SGPT (ALT) < 1%; SGOT (AST) < 1%; GGT < 1%; alkaline phosphatase < 1%; LDH < 1%; total bilirubin < 1%
Decreased WBC < 1%; elevated prothrombin time 1%
Elevated BUN 4%; elevated serum creatinine < 1%
GGT, alkaline phosphatase, and prothrombin time data are from adult studies only.
Caricin is contraindicated in patients with a known hypersensitivity to Caricin, erythromycin, or any of the macrolide antibacterial drugs.
Concomitant administration of Caricin with cisapride and pimozide is contraindicated [seeDRUG INTERACTIONS (7)].
There have been postmarketing reports of drug interactions when Caricin is coadministered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by Caricin. Fatalities have been reported.
Cholestatic Jaundice/Hepatic Dysfunction
Caricin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of Caricin.
Concomitant administration of Caricin and colchicine is contraindicated in patients with renal or hepatic impairment.
HMG-CoA Reductase Inhibitors
Do not use Caricin concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.
Concomitant administration of Caricin and ergotamine or dihydroergotamine is contraindicated.
Contraindications for Coadministered Drugs
For information about contraindications of other drugs indicated in combination with Caricin, refer to their full prescribing information (contraindications section).
Active ingredient matches for Caricin:
Clarithromycin in Vietnam.
|Unit description / dosage (Manufacturer)||Price, USD|
|Caricin 250 mg x 3 Blister x 4 Tablet|
|Caricin 500 mg x 3 Blister x 4 Tablet|
List of Caricin substitutes (brand and generic names):
|Calrcin 250 mg Tablet (Hinglaj Laboratories of India)||$ 0.41|
|Carimycin 250 mg x 10 x 10's|
|Celex (Chile, India, Thailand)|
|Tablet, Film-Coated; Oral; Clonixin Lysine 125 mg (Abbott India Ltd.)|
|CELEX Capsule/ Tablet / 500mg / 4 units (Abbott India Ltd.)||$ 4.39|
|CELEX Capsule/ Tablet / 250mg / 4 units (Abbott India Ltd.)||$ 2.24|
|Celex 250mg FC-TAB / 4 (Abbott India Ltd.)||$ 2.22|
|250 mg x 4's (Abbott India Ltd.)||$ 2.22|
|Celex 250 mg x 500's (Abbott India Ltd.)|
|Celex 500 mg x 10 x 10's (Abbott India Ltd.)|
|Celex 500 mg x 500's (Abbott India Ltd.)|
|Celex 125 mg/5 mL x 60 mL (Abbott India Ltd.)|
|Celex 500 mg Tablet (Abbott India Ltd.)||$ 1.10|
|Celex 250 mg Tablet (Abbott India Ltd.)||$ 0.56|
|CELEX film-coated tab 250 mg x 4's (Abbott India Ltd.)||$ 2.22|
|Celex cap 250 mg 500's (Abbott India Ltd.)|
|Celex cap 500 mg 10 x 10's (Abbott India Ltd.)|
|Celex cap 500 mg 500's (Abbott India Ltd.)|
|Celex dry syr 125 mg/5 mL 60 mL x 1's (Abbott India Ltd.)|
|Celex FC 250 mg Tablet (Glaxo Smithkline Pharmaceuticals Ltd.)||$ 0.56|
|CELEX OD Capsule/ Tablet / 500mg / 2 units (Abbott India)||$ 4.77|
|CELEX OD 500 MG TABLET 1 strip / 4 tablets each (Glaxo SmithKline Pharmaceuticals Ltd)||$ 5.87|
|Celex OD 500mg Tablet (Glaxo SmithKline Pharmaceuticals Ltd)||$ 1.47|
|Celex-OD 500mg TAB / 4 (Abbott)|
|500 mg x 4's (Abbott)|
|CELEX-OD coated tab 500 mg x 4's (Abbott)||$ 5.57|
|Chang Di (China)|
|Chem Mart Clarithromycin|
|Tablet; Oral; Clarithromycin 250 mg|
|Chemmart Clarithromycin (Australia)|
|Ciracle (South Korea)|
|Cla Ram (Nicaragua)|
|Clabact 250 mg x 2 Blister x 10 Tablet|
|Clabact 500 mg x 2 Blister x 7 Tablet|
|Clabet 500 mg x 50's (Umedica)|
|Clabet FC tab 500 mg 50's (Umedica)|
|Clabexid 125 mg x 20 Packs|
|Clacee (South Africa)|
- DailyMed. "CLARITHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "clarithromycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "clarithromycin". http://www.drugbank.ca/drugs/DB01211 (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Caricin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Caricin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
1 consumer reported time for resultsTo what extent do I have to use Caricin before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 1 week and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Caricin. To get the time effectiveness of using Caricin drug by other patients, please click here.
2 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology